Massive Bio is at the forefront of personalized oncology solutions, utilizing advanced technologies to enhance patient care and clinical trial accessibility. Central to their offerings is the SYNERGY-AI Clinical Trial Matching Solution, which employs artificial intelligence to connect cancer patients with relevant clinical trials based on their unique medical profiles. This AI-driven platform not only streamlines the process of finding suitable trials but also integrates genomic testing and biomarker analysis, allowing for a more tailored approach to cancer treatment. The introduction of their ChatGPT-powered chatbots, AskFiona AI and DrArturo AI, further exemplifies their commitment to improving patient and provider engagement, facilitating real-time communication and support throughout the clinical trial journey.

In addition to their innovative matching technology, Massive Bio emphasizes a comprehensive support system for patients. Their services include clinical coordination, continuous monitoring, and community support, ensuring that patients receive informed recommendations and guidance from a board of physicians. By leveraging telehealth, genomics, and smart data, Massive Bio aims to provide equitable access to cutting-edge therapies and emerging clinical trials, regardless of geographical or financial barriers. Their focus on compliance and security, adhering to regulations such as HIPAA and GDPR, underscores their dedication to maintaining patient confidentiality while advancing the field of oncology through data-driven insights and collaborative care.

United States

Massive Bio collects and curates the latest scientific knowledge in genomics of cancer, connects with clinical information incorporate all new discoveries in treatment plans.

Massive Bio

Company Details